Literature DB >> 28901026

On authorship in the BJCP.

Adam F Cohen1.   

Abstract

Mesh:

Year:  2017        PMID: 28901026      PMCID: PMC5595944          DOI: 10.1111/bcp.13385

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  5 in total

1.  Industrialized research in the BJCP: a neo-Luddite view.

Authors:  Adam F Cohen; James M Ritter
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

2.  On authorship in the BJCP.

Authors:  Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2017-10       Impact factor: 4.335

3.  Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.

Authors:  Anne Kerbrat; Jean-Christophe Ferré; Pierre Fillatre; Thomas Ronzière; Stéphane Vannier; Béatrice Carsin-Nicol; Sylvain Lavoué; Marc Vérin; Jean-Yves Gauvrit; Yves Le Tulzo; Gilles Edan
Journal:  N Engl J Med       Date:  2016-11-03       Impact factor: 91.245

4.  Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

5.  Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9.

Authors:  Eveline P van Poelgeest; Reinout M Swart; Michiel G H Betjes; Matthijs Moerland; Jan J Weening; Yann Tessier; Michael R Hodges; Arthur A Levin; Jacobus Burggraaf
Journal:  Am J Kidney Dis       Date:  2013-04-03       Impact factor: 8.860

  5 in total
  3 in total

1.  On authorship in the BJCP.

Authors:  Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2017-10       Impact factor: 4.335

2.  Goodbye to all that.

Authors:  Adam Cohen
Journal:  Br J Clin Pharmacol       Date:  2019-12-12       Impact factor: 4.335

3.  De-risking Clinical Trials: The BIAL Phase I Trial in Foresight.

Authors:  Adam F Cohen; Jeroen van Smeden; David J Webb
Journal:  Clin Pharmacol Ther       Date:  2021-12-28       Impact factor: 6.903

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.